QUICK FACTS

Company description:

A fast-growing, Boston-based biomedical company, TEI Biosciences has applied its expertise in regenerative medicine to develop and commercialize a suite of novel biologic products for a broad spectrum of soft tissue repair and reinforcement applications, including:

Dura, tendon, and hernia repair
Pelvic floor reconstruction
Wound management
Plastic and reconstructive surgery

TEI products offer compelling advantages:

They are packaged dry and have a three-year shelf life at room temperature
Can be trimmed to size wet or dry and placed in any orientation, with either side up
Rehydrate in saline solution in about 60 seconds
Provide superior handling and suturing characteristics – feel like natural tissue and readily conform to the surgical sites

TEI derives its products from fetal bovine dermis, one of the purest forms of collagen, using a proprietary process that preserves the beneficial properties of the natural collagen matrix. Biocompatible, cell-friendly, and intrinsically strong with no artificial chemical crosslinking, TEI devices are designed to promote rapid cell penetration and revascularization. They act as a scaffold that can be naturally and progressively integrated, remodeled, and eventually replaced by functional host tissue. Today, TEI has seven FDA-cleared products based on its proprietary biologic-matrix technology that it sells directly and through partnerships with some of the world's leading medical device companies: Medtronic Neurosurgery (Durepair®); Boston Scientific (Xenform®), and Stryker Orthopaedics (TissueMend®).

Growth Strategy:

TEI's mission is to continue its pioneering work in the field of tissue repair and regeneration through the development of new biologic devices. Future devices may carry active agents for fighting infections or managing pain. They may also be enhanced with human cells or growth factors designed for faster and more complete tissue regeneration.

More than sixty employees strong, TEI Biosciences has an accomplished team of scientists, engineers, product development managers, manufacturing operators, QC/QA specialists, and sales/marketing professionals

Board of Directors

Yiannis Monovoukas, Ph.D., MBA Chairman, President and CEO, TEI Biosciecnes

Millicent Bell, Ph.D. Professor Emerita, Literature, Boston University; author of many books and published articles

Anthony S. Bell Principal, Tony Bell AIA Architecture

Rebecca M. Bergman VP of Science & Technology, Medtronic, Inc.

Lewis H. Ferguson, III, Esq. Partner, Gibson Dunn & Crutcher LLP; Former General Counsel, PCAOB; Former Senior Vice President, General Counsel and Director, Wright Medical

John N. Hatsopoulos CEO AmericanDG Energy; Chairman, Glen Rose Capital LLC; Partner and Managing Director, Alexandros Partners LLC; Former President and Vice Chairman, Thermo Electron

Leonard Laster, MD Professor of Medicine, consultant, and author; Former Chancellor, University of Massachusetts Medical Center

Donald L. Laurie Managing Partner, Oyster International LLC; author; strategy and leadership consultant

Ownership and Financial Information:

TEI Biosciences is a privately held company, and as such, it does not release financial results.

Products and Applications:

Product	Clinical Need	Applications	Marketing & Sales
SurgiMend^®	General surgery Plastic & reconstructive Orthopedics	• Hernia repair • Breast reconstruction • Muscle-flap reinforcement • Tendon augmentation • Soft tissue reconstruction	TEI Biosciences
PriMatrix™	Wound management	• Skin ulcers • Second-degree burns • Surgical wounds	TEI Biosciences
Durepair^®	Neurosurgery	• Cranial dura mater • Spinal dura mater	Medtronic Neurosurgery
Xenform^®	Urology and urogynecology	• Pelvic floor prolapse	Boston Scientific
TissueMend^®	Orthopedics	• Tendon augmentation	Stryker Orthopaedics

Company headquarters

7 Elkins Street
Boston, Massachusetts
02127 USA
866.524.0022 (toll-free)
617.268.1616
www.teibio.com